Skip to main content
. Author manuscript; available in PMC: 2017 Aug 2.
Published in final edited form as: Sci China Life Sci. 2016 Jun 22;59(9):920–929. doi: 10.1007/s11427-016-0020-y

Figure 3.

Figure 3

Therapeutic strategies to target Shh signaling pathway. The Shh signaling could be blocked at different levels, including Shh ligand inhibitors, Smo receptor inhibitors and transcriptional factors Gli inhibitors. Among these antagonists, Smo inhibitors (cyclopamine and IPI-926) and Gli inhibitors (Darinaparsin and GANT61) are tested in the setting of fibrotic CKD. Except for IPI-926 (Fabian et al., 2012), all Shh signaling inhibitors are able to attenuate renal fibrosis in experimental models.